Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

187.25 -0.55 (-0.29%)

Streaming Delayed Price Updated: 12:14 PM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

59 60 Next >

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

May 03, 2023

Via Benzinga

Why Eli Lilly Stock Is Bolting Higher Today ↗

May 03, 2023

Lilly's Alzheimer's disease candidate might be a best-in-class option for patients.

Via The Motley Fool

Biogen Unusual Options Activity For May 03 ↗

May 03, 2023

Via Benzinga

Another Sucess In Alzheimer’s Disease ↗

May 03, 2023

Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?

Via Talk Markets

Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises ↗

May 03, 2023

Eli Lilly is focusing on proteins associated with Alzheimer's disease.

Via Investor's Business Daily

Microsoft, Snap And 2 Other Stocks Insiders Are Selling ↗

May 03, 2023

The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Biotech Is Back With Guggenheim Upgrade: What You Need To Know ↗

May 01, 2023

Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD)...

Via Benzinga

Looking At Biogen's Recent Unusual Options Activity ↗

April 28, 2023

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗

April 26, 2023

Via Benzinga

Biogen Earnings Perspective: Return On Capital Employed ↗

April 26, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock ↗

May 01, 2023

Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 28, 2023

Via Benzinga

These Analysts Revise Price Targets On Biogen Following Q1 Results ↗

April 26, 2023

Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter.

Via Benzinga

Biogen On The Hunt ↗

April 25, 2023

Biogen is in the process of culling its pipeline to prepare for its upcoming deal making. What is happening and what does it mena?

Via Talk Markets

Earnings Outlook For Biogen ↗

April 24, 2023

Via Benzinga

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗

April 28, 2023

Microsoft, Meta, Cloudflare and Crocs were among the many big movers.

Via Investor's Business Daily

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy ↗

April 28, 2023

Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023

Via InvestorPlace

Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA ↗

April 26, 2023

The FDA approved Biogen Inc's (NASDAQ:

Via Benzinga

Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

April 26, 2023

Morgan Stanley raised the price target for Alphabet Inc. (NASDAQ: GOOGL) from $135 to $140. Morgan Stanley analyst Brian Nowak maintained an Overweight rating. Alphabet shares fell 1% to $102.83 in...

Via Benzinga

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

April 25, 2023

From Biogen Inc.

Via GlobeNewswire

What's Going On With Biogen Stock Tuesday? ↗

April 25, 2023

Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.

Via Benzinga

Biogen Inc. Beats Q1 Earnings And Revenue Estimates ↗

April 25, 2023

Biogen Inc. came out with quarterly earnings of $3.40 per share.

Via Talk Markets

Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs ↗

April 25, 2023

Via Benzinga

Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful ↗

April 25, 2023

The company is hopeful for maintenance dosing and a new injection of the drug.

Via Investor's Business Daily

3 Top Biotech Stocks Defying the Bear Market ↗

April 25, 2023

All three companies have therapies with strong sales potential.

Via The Motley Fool

Why Legend Biotech Stock Is Having Its Best Month Yet

April 25, 2023

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

Via MarketBeat

Why Shares of Keros Therapeutics Jumped This Week ↗

April 21, 2023

The company appointed a new director and an analyst reiterated his position on the stock.

Via The Motley Fool

Biogen To Report Q1 Earnings: Here's What To Expect ↗

April 21, 2023

We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%.

Via Talk Markets

Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! ↗

April 21, 2023

Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid...

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.